Compare GENC & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GENC | IKT |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.0M | 215.2M |
| IPO Year | 1995 | 2020 |
| Metric | GENC | IKT |
|---|---|---|
| Price | $14.82 | $1.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $17.60 | $5.00 |
| AVG Volume (30 Days) | 28.0K | ★ 660.0K |
| Earning Date | 02-06-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.08 | ★ 57.76 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $48,943,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.51 | N/A |
| P/E Ratio | $63.83 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.22 | $1.33 |
| 52 Week High | $17.40 | $2.26 |
| Indicator | GENC | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 38.77 |
| Support Level | $14.57 | $1.51 |
| Resistance Level | $15.66 | $1.74 |
| Average True Range (ATR) | 0.46 | 0.09 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 54.47 | 36.54 |
Gencor Industries Inc and its subsidiaries are a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company's products are manufactured in the United States and sold through a combination of Company sales representatives and independent dealers and agents. The Company has one reporting segment, equipment for the highway construction industry. The Company's principal core products include asphalt pavers, hot mix asphalt plants, combustion systems, and fluid heat transfer systems. It operates in the United States, Canada, and other foreign countries, with the majority of revenue coming from the United States.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.